It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
Announcement of the national program “MOVER” raises expectations for an increase in patent filings for green technology
-
UPC “saisie-contrefaçon” Part III: the “C-Kore” case
-
Brazil: Animal Health and Patent Litigation
-
China’s Supreme People Court decides FRAND dispute in ACT v Oppo
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
Random Articles:
-
The Italian Antitrust Authority investigates on Pfizer for abuse of a dominant position by the enforcement of patents
-
A Japanese version Amicus Brief system will be introduced in spring 2022
-
Spain: Supreme Court, First Civil Law Chamber, 531/2014, 15 October 2014
-
Equivalents, Extent of Protection, Infringement, Litigation, Pharma, Pharmaceutical patent, Scope of protection, United Kingdom
Actavis and Equivalents – One Year On
-
EPO: T1691/15, European Patent Office (EPO), Board of Appeal, T1691/15, 27 July 2016
-
UPC platform to practice entry into force functionalities
-
Ratification by Belgium of the UPC agreement
-
Petition for ministerial conference on European Patent Organisation
-
Monopoly on Test Results? Protection of Immaterial Products as “Fruits” of a Patented Method under Sec. 9 (3) German Patent Act
-
Basics of the Unitary Patent system. Part 1: What is a Unitary Patent?